318 related articles for article (PubMed ID: 33712866)
1. Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Stockklausner C; Duffert CM; Cario H; Knöfler R; Streif W; Kulozik AE;
Ann Hematol; 2021 Jul; 100(7):1647-1665. PubMed ID: 33712866
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
3. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
4. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.
Nelson ND; Marcogliese A; Bergstrom K; Scheurer M; Mahoney D; Bertuch AA
Pediatr Blood Cancer; 2016 Aug; 63(8):1484-7. PubMed ID: 27100794
[TBL] [Abstract][Full Text] [Related]
6. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
8. Contemporary management of essential thrombocythemia in children.
Randi ML; Bertozzi I; Putti MC
Expert Rev Hematol; 2019 May; 12(5):367-373. PubMed ID: 30925843
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
10. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
12. Identification of putative noncanonical driver mutations in patients with essential thrombocythemia.
Arai A; Yoshimitsu M; Otsuka M; Ito Y; Miyazono T; Nakano N; Obama K; Nakashima H; Hanada S; Owatari S; Nakamura D; Tokunaga M; Kamada Y; Utsunomiya A; Haraguchi K; Hayashida M; Fujino S; Odawara J; Tabuchi T; Suzuki S; Hamada H; Kawamoto Y; Uchida Y; Hachiman M; Ishitsuka K
Eur J Haematol; 2023 Jun; 110(6):639-647. PubMed ID: 36811253
[TBL] [Abstract][Full Text] [Related]
13. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
14. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
[TBL] [Abstract][Full Text] [Related]
15. [Clinical application of gene mutation information in myeloproliferative neoplasms].
Takenaka K
Rinsho Ketsueki; 2019; 60(6):610-618. PubMed ID: 31281152
[TBL] [Abstract][Full Text] [Related]
16. Thrombocytosis.
Skoda RC
Hematology Am Soc Hematol Educ Program; 2009; ():159-67. PubMed ID: 20008195
[TBL] [Abstract][Full Text] [Related]
17. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
[TBL] [Abstract][Full Text] [Related]
18. New advances in the pathogenesis and therapy of essential thrombocythemia.
Levine RL; Heaney M
Hematology Am Soc Hematol Educ Program; 2008; ():76-82. PubMed ID: 19074062
[TBL] [Abstract][Full Text] [Related]
19. A Rare Case of Essential Thrombocythemia with Coexisting
Jang MA; Seo MY; Choi KJ; Hong DS
J Korean Med Sci; 2020 Jun; 35(23):e168. PubMed ID: 32537949
[TBL] [Abstract][Full Text] [Related]
20. The MPL mutation.
Guglielmelli P; Calabresi L
Int Rev Cell Mol Biol; 2021; 365():163-178. PubMed ID: 34756243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]